Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. - Wikidata - wikimedia - TriplyDB

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

http://www.wikidata.org/entity/Q34361680

about

Structural mechanism of trimeric HIV-1 envelope glycoprotein activation A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Structure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation † , ‡A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Current views on the potential for development of a HIV vaccine.Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition.Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

P2860

Q21131394-BC2BCCDC-C864-40ED-AD1F-059136F9D9F4 Q27302081-42A298DD-6C18-49AE-834C-28DA1FCEDDCB Q27489000-BBCA9BC0-4459-4982-B914-92E12619757F Q27644383-8FCC2C7D-EE1B-4E83-8483-EBF9E501A15C Q27653846-0B71F19B-1005-4601-B02D-2A272F98878B Q27675032-2873097D-56B4-4820-B396-9483B4B4F205 Q27675486-DB5A869F-69A4-4CC6-8857-C2646D63D2FD Q27678062-A42E6B2E-2482-48DB-B6C1-078D20F2D163 Q27678306-7BFB8CF7-9BB0-4146-B642-2C8D4E0B6F2D Q27680442-86F297AB-692C-44BF-BE21-0AA09E8993FE Q27680496-23FCEF58-761D-4E6D-B0BD-CDC0B0813673 Q27680497-DCB906B2-C028-4ACB-9657-EC640AEBBA67 Q27683553-92792296-BB4F-4A60-9185-69AF967E2B19 Q28271300-EFF3F2C2-5015-47E3-9F08-6E57A7F07BD8 Q28299280-AE10DBBE-8A42-41C3-B10A-2F44522E7B39 Q28749755-D957981A-D550-4069-B89F-9840F5E63C8D Q29306052-987B24A2-C26F-4DC7-BF78-3906B47BE33D Q29619015-D67CDE9D-2EA4-4022-8817-AAA3FB9800D4 Q30234577-FAB80311-DE07-408A-AE8F-0FA97A9CD06E Q30360326-FD1F669B-96B6-43E8-8053-354759DE6452 Q30379200-A7A60B56-D8F4-477B-A7E7-4D818DF8991F Q30397595-895E201F-E310-4C67-9A0B-5665CAD46AD5 Q30408097-D4BC9FAB-B5E9-47B1-A544-6D3CE5DD515C Q30454762-53EF4D9C-4A05-45B8-A3D7-E6C408A4ABBA Q30490942-390CD992-ECA6-4B5E-A136-5C038423A026 Q30499561-8CD6555D-D2C2-41BC-869D-DC05EAB7B116 Q30580101-7B06B15F-7C2F-4F0E-991E-54DB91E7F36B Q30657338-56D2B68F-37E4-4C98-BD71-89EED2327D77 Q31036522-9750ED37-8F60-43C2-81E1-FE7356C4FB57 Q33373664-9C57CB8D-E728-4A25-9622-DA5D3DE80DA0 Q33571825-B29BFF95-B95F-4252-B608-A14B5230287A Q33601372-F81D6C64-2D14-48A4-B84E-7466A31CF8EC Q33614605-0955B69F-367E-4B3F-9925-FD8809C97F06 Q33711154-86D89DA0-EB4B-428F-88E7-2F89B396653A Q33753573-9C681B11-BF37-44EF-8E73-0F937340A9BA Q33788792-60708416-2A59-4B9D-908F-959398C44176 Q33821896-A1921115-BC61-4D52-A0CE-70E6088D4017 Q33830824-B7DD2180-2A20-481C-88DC-16D2A7DAAA74 Q33883887-AD4D4557-EE89-450A-B118-12CE3BB1A7B9 Q33930424-E9098040-5334-48DC-87D2-D9782F5EC5AF

P2860

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

http://www.wikidata.org/entity/Q34361680

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@ast

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@en

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@nl

type

label

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@ast

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@en

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@nl

prefLabel

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@ast

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@en

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@nl

P1433

Q34361680-C551AC7A-D977-44AA-B157-27F886102A5A

P1476

Q34361680-7F575878-D927-4BC9-ADD8-304279C861D0

P2093

Q34361680-03EF2464-F940-4779-9177-197DE75E060D

Q34361680-2125CCF6-F622-43F1-A77A-CC70AA2AA841

Q34361680-22279B4F-BDCA-41F2-9693-CD1879D06A60

Q34361680-2409C32A-C05F-4AEA-ADFA-7CEF760E75ED

Q34361680-4320E3EE-AF44-40A0-8BE2-800FA5D382A7

Q34361680-81EB661C-2759-4D18-B783-BC30E064D0D5

Q34361680-8FFAB7C0-DDAB-4CC4-ACFA-0CC1FFCF858F

Q34361680-92FB48E6-D4BB-451C-AA35-72615E3DC037

Q34361680-DB3D4F8D-C532-4FB5-8A3E-2A977E8364BD

Q34361680-F4C6F773-9C28-44B6-93A2-8F4CDBB0BE0C

P2860

Q34361680-01FBAF8E-97A7-4564-BC19-7669FC856B32

Q34361680-0B90CA8D-35B0-4A95-9A6D-92C4B77B75BF

Q34361680-0C20996C-083D-4CBD-A743-4A406B4D8C1E

Q34361680-14C9F771-1958-424D-B9F6-55A83915C439

Q34361680-1D9A360D-AEDE-4F23-9EC1-3F3557DCCECB

Q34361680-20B431D1-AA54-42C4-B4D1-8F545DA67DBE

Q34361680-21A3BDEE-3C66-4846-B33F-78B5A19275B2

Q34361680-221C9068-0B26-4BE4-9341-05DCFE724B2E

Q34361680-235E7011-7F6B-41B2-9E64-4C92EE77EBDA

Q34361680-281659F9-6C5D-4027-941A-8EC955E06058

P304

Q34361680-50D2BD95-4441-4CF9-9068-28613E1EFCC8

P31

Q34361680-70095569-8C31-4AEF-8719-E187349CF148

P356

Q34361680-B11540A7-CBCE-44A4-839A-4BBAFC0898CC

P407

Q34361680-A6232B36-6AA3-431A-A953-A7B1A46BF2E7

P433

Q34361680-14ED9C35-2568-4AE4-AEFC-F7B5FBE6718E

P478

Q34361680-2AB16F5A-5D4C-4EA2-A928-3581045D9581

P50

Q34361680-9EFCA739-2CA6-48A4-B6BA-9CE29AF21E2C

P577

Q34361680-5EACE1C1-4360-42D6-806A-20E9F82034A0

P5875

Q34361680-A12C7E43-8EA8-4B6A-A22C-55FC5A188C65

P698

Q34361680-D7016295-B38E-4F69-BBF4-3161F7F023A7

P932

Q34361680-F6F0F97D-9228-4D74-8060-89F0331AC78F

P356

JVI.76.17.8875-8889.2002

P1433

Journal of Virology

P1476

Stabilization of the soluble, ...... immunodeficiency virus type 1.

@en

P2093

Aditi Master

http://www.w3.org/2001/XMLSchema#string

John P Moore

http://www.w3.org/2001/XMLSchema#string

Linnea Schiffner

http://www.w3.org/2001/XMLSchema#string

Maciej Paluch

http://www.w3.org/2001/XMLSchema#string

Mika Vesanen

http://www.w3.org/2001/XMLSchema#string

Min Lu

http://www.w3.org/2001/XMLSchema#string

Norbert Schuelke

http://www.w3.org/2001/XMLSchema#string

Paul J Maddon

http://www.w3.org/2001/XMLSchema#string

Rogier W Sanders

http://www.w3.org/2001/XMLSchema#string

Roopa Kalyanaraman

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41

The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts.

Trimerization specificity in HIV-1 gp41: analysis with a GCN4 leucine zipper model

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: implications for membrane fusion

Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.

Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complex

Structure of influenza haemagglutinin at the pH of membrane fusion

Crystal structure of an isoleucine-zipper trimer

P304

8875-8889

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.76.17.8875-8889.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11222410

http://www.w3.org/2001/XMLSchema#string

P698

12163607

http://www.w3.org/2001/XMLSchema#string

P932

136973

http://www.w3.org/2001/XMLSchema#string